Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Novo Nordisk and Health2Sync Partner on Diabetes App, Erasca Raises $64 Million, Invitae Expecting to Raise $171M in Common Stock Offering

  • 2019-03-13T09:06:00.000+0000
  • California
  • Author: Lauren Panetta

3/12/19 – FiercePharma
Lilly's Cyramza scores in targeted lung cancer—but major competition awaits

3/12/19 – Biospace
CURE Pharmaceutical Snags DEA License to Manufacture Pharmaceuticals From Cannabis

3/12/19 – FierceBiotech
With positive phase 2, Neurocrine eyes trial for CAH drug

3/12/19 – San Diego Union-Tribune
Would you eat algae? Triton Algae Innovations receives FDA acceptance for their edible algae

3/11/19 – GEN
23andMe Offers Test for Elevated Risk of Type 2 Diabetes

3/11/19 – FierceBiotech
Novo Nordisk, Health2Sync partner to bring diabetes app to Japan

3/11/19 – FierceBiotech
Celgene's MS drug ozanimod gets EU filing

3/8/19 – San Diego Union-Tribune
Cancer drug company Oncternal takes reverse merger route to stock market

3/7/19 – GenomeWeb
uBiome, University of Louisville Partner on IBD Study

3/7/19 – FierceBiotech
Oncternal grows by merger again, this time swallowing GTx

3/6/19 – San Diego Union-Tribune
Biotech startup raises $64 million to erase cancer — it's even in the name

3/6/19 – GenomeWeb
Invitae Expects to Raise at Least $171M in Common Stock Offering

3/6/19 – Endpoints
Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

3/6/19 – GenomeWeb
Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx

3/5/19 – GEN
Merck KGaA, Pfizer Join BioXcel-Nektar Collaboration, Creating Triple Combination Therapy for Pancreatic Cancer

3/5/19 – FierceBiotech
Pfizer licenses AnTolRx's immune tolerance medicine for diabetes

3/5/19 – GEN
Sartorius Stedim Biotech, Novasep Partner on Membrane Chromatography

3/5/19 – FierceBiotech
Astellas taps ReForm to improve clinical-phase biologics

3/4/19 – FierceBiotech
Biogen strikes $877M Nightstar gene therapy buyout

3/1/19 – Scrip
Horizon Pharma Sees Mid-2019 BLA For Tepro After Solid Phase III TED Data